Loading...
CASI Pharmaceuticals, Inc.
CASI•NASDAQ
Healthcare
Biotechnology
$1.33
$-0.51(-27.72%)
CASI Pharmaceuticals, Inc. (CASI) Financial Performance & Statements
Review CASI Pharmaceuticals, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
-15.77%
↓ 15.77%
Operating Income Growth
-57.98%
↓ 57.98%
Net Income Growth
-45.73%
↓ 45.73%
Operating Cash Flow Growth
-46.36%
↓ 46.36%
Operating Margin
-138.02%
↓ 138.02%
Gross Margin
39.06%
↑ 39.06%
Net Profit Margin
-137.57%
↓ 137.57%
ROE
-390.76%
↓ 390.76%
ROIC
-228.70%
↓ 228.70%
CASI Pharmaceuticals, Inc. (CASI) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for CASI Pharmaceuticals, Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $13.36M | $7.79M | $3.98M | $3.41M |
| Cost of Revenue | $10.13M | $3.75M | $1.91M | $1.60M |
| Gross Profit | $3.23M | $4.04M | $2.07M | $1.81M |
| Gross Profit Ratio | $0.24 | $0.52 | $0.52 | $0.53 |
| R&D Expenses | $3.67M | $1.52M | $1.25M | $2.48M |
| SG&A Expenses | $11.92M | $10.61M | $10.37M | $8.55M |
| Operating Expenses | $16.14M | $12.51M | $10.86M | $11.03M |
| Total Costs & Expenses | $26.27M | $16.26M | $12.77M | $12.63M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $55000.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $379000.00 | -$3.39M | $935250.00 |
| EBITDA | -$10.34M | -$8.09M | -$12.18M | -$8.28M |
| EBITDA Ratio | -$0.77 | -$1.04 | -$3.06 | -$2.43 |
| Operating Income | -$12.91M | -$8.46M | -$8.79M | -$9.22M |
| Operating Income Ratio | -$0.97 | -$1.09 | -$2.21 | -$2.70 |
| Other Income/Expenses (Net) | -$1.38M | $1.19M | $1.82M | -$309000.00 |
| Income Before Tax | -$14.30M | -$7.28M | -$6.96M | -$9.53M |
| Income Before Tax Ratio | -$1.07 | -$0.93 | -$1.75 | -$2.79 |
| Income Tax Expense | $73000.00 | $1.12M | $0.00 | $362724.00 |
| Net Income | -$14.37M | -$8.39M | -$6.96M | -$9.53M |
| Net Income Ratio | -$1.08 | -$1.08 | -$1.75 | -$2.79 |
| EPS | -$0.94 | -$0.55 | -$0.52 | -$0.71 |
| Diluted EPS | -$0.94 | -$0.55 | -$0.52 | -$0.71 |
| Weighted Avg Shares Outstanding | $15.49M | $15.29M | $13.52M | $13.38M |
| Weighted Avg Shares Outstanding (Diluted) | $15.49M | $15.29M | $13.52M | $13.38M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan